Depo-provera Injection, Suspension
Product Images NDC 0009-0746

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Depo-provera (NDC 0009-0746). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Depo Provera 01)

A forest plot chart showing odds ratios with 95% confidence intervals for various studies evaluating risk associated with DMPA use. Studies from 1987 to 2012 are listed, including Lee et al., Paul et al., WHO, Shapiro et al., and Li et al. The x-axis uses a logarithmic scale for odds ratios ranging from 0.6 to 7.4, with a vertical line at 1.0 indicating no increased risk.*

FDA Label Image

Chemical Structure (Depo Provera 02)

Chemical structure of medroxyprogesterone acetate, the active ingredient in Depo-Provera injection suspension.*

FDA Label Image

Logo (Depo Provera 03)

Label fragment showing the Pfizer logo and distributor information for Pharmacia & Upjohn Company LLC, a division of Pfizer Inc., New York, NY 10017. This label is associated with Depo-Provera injection suspension.*

FDA Label Image

Chart (Depo Provera 03a)

A vertical diagram illustrating birth control methods ranked by pregnancy likelihood per 100 women per year. Methods with fewer pregnancies include implants, injections, intrauterine devices, and sterilization at the top. Mid-level methods include birth control pills, skin patches, and vaginal rings with hormones, condoms, and diaphragms. Methods associated with more pregnancies include abstinence during fertile days, spermicide, withdrawal, and no birth control at the bottom.*

FDA Label Image

Depo Provera 03b

FDA Label Image

Principal Display Panel (150 mg/mL Vial Label)

Label for Depo-Provera contraceptive injection, medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL strength. The label indicates it is for intramuscular use only, single-dose vial, with dosing and use instructions referencing accompanying prescribing information. Manufactured by Pharmacia & Upjohn Company LLC, Division of Pfizer Inc.*

FDA Label Image

Principal Display Panel (150 mg/mL Vial Carton)

Depo-Provera Contraceptive Injection 150 mg/mL, containing medroxyprogesterone acetate injectable suspension, USP, in 1 mL single-dose vials. Packaging label shows branding by Pfizer and distribution by Pharmacia & Upjohn Co. The label specifies intramuscular administration and storage instructions for vials at controlled room temperature (20° to 25°C).*

FDA Label Image

Principal Display Panel (1 mL Syringe Label)

Label for Depo-Provera 150 mg/mL Contraceptive Injection by Pfizer, a medroxyprogesterone acetate injectable suspension for intramuscular use. The label indicates a 1 mL single dose syringe with instructions to shake vigorously before use, and includes the NDC 0009-7376-11 and Pfizer contact information.*

FDA Label Image

Principal Display Panel (1 mL Syringe Carton)

Depo-Provera Contraceptive Injection 150 mg per mL injectable suspension label by Pfizer. The label indicates medroxyprogesterone acetate as the active ingredient, specifies intramuscular use, single-use 1 mL prefilled syringe format, and includes preparation and needle activation instructions along with storage information. Distributed by Pharmacia & Upjohn Co, division of Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.